α-2,3-sialyltransferase

α-2,3-sialyltransferase-IN-1 (Lith-O-Asp analog) is an α-2,3-sialyltransferase inhibitor with anticancer activity. Vapendavir diphosphate inhibits EV71 replication.

ST3 β-Gal α-2,3-Sialyltransferase 1 (ST3GAL1) is a sialyltransferase enzyme that, when overexpressed in ovarian cancer cell lines, enhances cell growth, migration, and invasion, while also increasing tumorigenicity and resistance to paclitaxel in vivo. ST3GAL1 catalyzes the transfer of sialic acid from CMP-sialic acid to galactose-containing substrates and is useful in studies of cancer progression and chemotherapy resistance.

ST3 β-Gal α-2,3-Sialyltransferase 5 (ST3GAL5) is an enzyme involved in glycosphingolipid (GSL) biosynthesis, known to inhibit TGF-β-induced epithelial-mesenchymal transition (EMT), invasion, and metastasis both in vivo and in vitro. ST3 β-Gal α-2,3-Sialyltransferase 5 is applicable for cancer research.

ST3 beta-Gal alpha-2,3-Sialyltransferase 2 (EC:2.4.3.4, ST3GAL2) catalyzes the transfer of sialic acid from CMP-sialic acid to galactose-containing substrates.

ST3 beta-Gal alpha-2,3-Sialyltransferase 6 (EC:2.4.99., ST3GAL6; SIAT10, Type 2 lactosamine alpha-2,3-sialyltransferase) is responsible for transferring sialic acid from activated cytidine 5'-monophospho-N-acetylneuraminic acid to terminal positions on sialylated glycolipids (gangliosides) or to N- or O-linked glycans on glycoproteins. This enzyme plays a significant role in cancer.

Alpha-2-3,6-sialidase (BiNanH2), a sialyltransferase commonly utilized in biochemical research, catalyzes the transfer of α-2,3/2,6-sialyl from CMP-Neu5Ac to galactoside acceptors [1].